Q2 FY2026 EarningsQ3 FY26 preliminary results missed revenue expectations, guided at $410M-$412M vs. $416.3M consensus, primarily due to a $7M impact from July flooding at the Cincinnati facility. Adjusted EPS of $0.55-$0.59 is in-line with the $0.56 mean. However, full-year FY26 revenue guidance was lowered to $1.634B-$1.654B (vs. $1.654B-$1.695B previously), and adjusted EPS was cut to $2.30-$2.40 (vs. $2.40-$2.50), reflecting prolonged recovery timelines with full operations not expected until Q2 FY27.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Integra LifeSciences(IART) the Revenue is 418.76 M (+0.76%), Beat estimate;the EBIT is 68.51 M (+12.85%), Beat estimate;the EPS is 0.06 (+101%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.42B0.76%
0.42B0.47%
+0.00B0.29%
EBITExceed expectations
0.07B12.85%
0.06B0.65%
+0.01B12.20%
EPSMiss expectations
0.06100.95%
0.065101.03%
-0.00500.08%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf